Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today in Science.
Press releases published on May 13, 2025

Remedy Plan Therapeutics Raises $18 Million Financing to Accelerate Advancement of Lead Asset RPT1G into Phase 1/2 Trials
Financing includes participation from Schooner Capital, Alexandria Venture Investments, and other existing investors Investment accelerates advancement of RPT1G, a novel NAMPT inhibitor, into a Phase 1/2 trial in patients with acute myeloid leukemia (AML) …

Disc Medicine to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference
WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious …

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments
WILMETTE, Illinois, May 13, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today …

Acronis Ecosystem Reaches 300 Technology Integrations, Drives New Opportunities for MSPs and ISVs
SHAFFHAUSEN, Switzerland, May 13, 2025 (GLOBE NEWSWIRE) -- Acronis, a global leader in cybersecurity and data protection, today announces a significant milestone in the Acronis Technology Ecosystem, which now includes nearly 300 integrations, reinforcing …

CareCloud Named “Top Healthcare IT Pick for 2025” by Maxim Group; AI Initiative Recognized as Key Growth Driver
SOMERSET, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDO) (“CareCloud” or the “Company”), a leader in healthcare technology and generative AI solutions, today announced that Maxim Group, LLC (“Maxim Group”), a leading …

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results
Topline pharmacodynamic biomarker, safety and tolerability results from a Phase 1 study of OV329 are on track to readout in Q3 2025 Ovid’s first program in its KCC2 direct activator library, OV350, has been dosed in a Phase 1 study in Q1 2025; safety and …

Mindera Health™ announces publication of randomized, prospective clinical utility study demonstrating improved psoriasis patient outcomes
Vista, CA, May 13, 2025 (GLOBE NEWSWIRE) -- Mindera Health, a leader in precision medicine for dermatological conditions, today announced positive results from the completion of a randomized, prospective clinical trial (MATCH) aimed at demonstrating the …

MicroAlgo Inc. Develops Blockchain-Based Traceable IP Rights Protection Algorithm
shenzhen, May 13, 2025 (GLOBE NEWSWIRE) -- MicroAlgo Inc. Develops Blockchain-Based Traceable IP Rights Protection Algorithm Shenzhen, May. 13, 2025/––MicroAlgo Inc. (the "Company" or "MicroAlgo") (NASDAQ: MLGO), today announced the development of a …

Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
Topline data expected by year end Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 13, 2025 (GLOBE …

Bionano Laboratories Announces Publication of the Largest Study To-Date Evaluating Clinical Utility of Optical Genome Mapping Across Multiple Hematologic Malignancies
In 58% or 303 of 519 cases, optical genome mapping (OGM) revealed somatic aberrations that were not detected by the standard cytogenetic workup (SCGW), including Tier 1, Tier 2 and Tier 3 structural variants (SVs) and copy number variants (CNVs) In 15% or …

Bagel Market Size to worth USD 8.99 Billion by 2032, says Coherent Market Insights
Burlingame, CA, May 13, 2025 (GLOBE NEWSWIRE) -- The global bagel market size was valued at USD 6.30 Billion in 2025 and is expected to reach USD 8.99 Billion by 2032, growing at a compound annual growth rate (CAGR) of 5.2% from 2025 to 2032, as …

UPCX Becomes Official Associate Partner of Formula E Tokyo E-Prix 2025, Advancing Web3 and Sustainable Mobility
Singapore, May 13, 2025 (GLOBE NEWSWIRE) -- UPCX, a leading blockchain-based open-source payment platform, is thrilled to announce its official sponsorship of the ABB FIA Formula E World Championship Tokyo E-Prix 2025 as an Associate Partner. This landmark …

iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
– GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival – Based on totality of data, iTeos and GSK have agreed to terminate the belrestotug development program – iTeos has initiated a …

Consumer expert Lady Janey claims businesses could lose out with overreliance on AI in customer service
TEWKESBURY, United Kingdom, May 13, 2025 (GLOBE NEWSWIRE) -- A consumer expert has said businesses must put customers at the forefront of any plans to expand the use of AI - or risk losing trade. Jane Hawkes, from the Lady Janey blog, said UK brands “risk …

Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment
Raanana, Israel, May 13, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, recently announced the initiation of …

Intuitive Machines Reports First Quarter 2025 Financial Results
HOUSTON, May 13, 2025 (GLOBE NEWSWIRE) -- Intuitive Machines, Inc. (Nasdaq: LUNR, “Intuitive Machines,” or the “Company”), a leading space technology and infrastructure services company, today announced its financial results for the first quarter ended …

Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights
Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027 LONDON, May 13, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“ …

Knight to Present at the 2025 RBC Capital Markets Global Healthcare Conference in New York City
MONTREAL, May 13, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to participate in a …

MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers
YAVNE, Israel, May 13, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the publication of a peer-reviewed post hoc analysis in Wounds. The analysis is …

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study
- ATTRibute-CM, BridgeBio’s Phase 3 clinical trial of acoramidis in patients with ATTR-CM, achieved statistical significance in reducing the risk of ACM or first CVH versus placebo in ATTRv-CM patients (59.1% risk reduction), establishing the mechanistic …